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Abstract
Shingles is an infection of the varicella zoster virus (VZV) and known as herpes zoster
(HZ) with recurrence. Children who have been vaccinated with varicella seem to have a lower
rate of HZ than individuals who were exposed to the wild-type VZV (Centers for Disease
Control, 2016). At this time, 99.5% of the United States population over the age of 40 have been
infected with the wild-type VZV (CDC, 2016). This may mean that recurrence will be increased
in our aging population. Currently, the rate is highest amongst the older adults 60 years old and
older (CDC, 2016). The incidence rate among this population is 10 cases per 1,000/year (CDC,
2016).
This report provides an overview of a patient who came into the office with a final
diagnosis of shingles: at the age of 67 years old, without documentation of varicella vaccination,
or having realized he had a rash. The clinician's ability to assess and formulate differential
diagnosis is vital to correct diagnosis, treatment, and education. The importance of piecing
together the classic signs of HZ along with comparing differential diagnoses, such as herpes
simplex virus (HSV) is critical, as education and treatment between the two viruses will be
varied.
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Background
A white male presented to his primary care office with a chief complaint of back pain. He
also stated he fell two or four days ago on ice. Because of this information, the student conducted
a musculoskeletal exam to begin. Upon further investigation, he stated the pain to feel like hot
pins and needles. The pain radiated to his right thigh originating from his right lower back.
Looking at his chart this patient was 67 years old without a history of shingles vaccination.
When his shirt was lifted, a classic vesicular rash was visualized on his right lower back, which
he probably could not see himself.
Initially, the diagnosis was missed. Because of this incident, the student became
interested in the topic of rate of recurrence of shingles. Investigating the recurrence rate led to
studies with information on treatment options for patients with reactivation of VZV, known as
herpes zoster (HZ). Studies that were reviewed showed no known rate of recurrence of VZV. To
this date, the CDC does not have data on the rate of recurrence of VZV. To conclude, articles
were examined until the most recent study was found to reveal that recurrence might, in fact, be
more common than previous researchers may have believed.
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Patient Case
History
The patient made a primary care appointment for chief complaint of back pain. Upon interview,
the patient reported falling two or four days ago on ice. He denied using any assistive device and
stated he lived alone. The patient was a sixty-seven year old Caucasian male residing in a private
home. He denied any recurrent falls since the one mentioned during the interview. He denied
other injuries such as bruising or history of skin ulcers but stated the pain in his back radiated to
his right thigh. The patient could not pinpoint how far the pain radiated.
For pain control, the patient was taking Tylenol at home 325mg tablets (two at a time a
couple times a day at most), which he also took for a history of bilateral knee arthritis. Other than
arthritis the patient stated he has a history of reflux, which he uses Protonix 40mg daily. His pain
was worse with activity which was reported to go up to a 7-8 on the 0-10 verbal pain scale.
During the visit, the pain was rated at a 6 out of 10. The patient denied any history of back pain
such as this, and when asked to characterize pain he stated, "hot pins and needles." The pain
seemed to be constant but could become worse if laying down on his back or with activity. He
also stated ice was attempted for relief but made the pain worse.
Looking over his immunization history there was influenza vaccine 2016 and Tdap in
2015. The patient did not currently drink alcohol, smoke, or use smokeless tobacco products. The
patient denied any history of surgeries and family history of back problems. He denied any
known allergies to medications or food. He also denied any past imaging of his back.
For the patient's review of systems, he denied any chest pain, palpitations, shortness or
breath, or a current cough. The patient was asked if there were any abnormalities in his urination
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including weak stream, nocturia, or difficulty with urination – all which were denied. The patient
also denied any trouble with constipation, diarrhea, blood in stools, or abdominal pain.
Regarding his musculoskeletal, the patient denied any gait imbalance, weakness, catching,
locking, or giving way of his bilateral lower extremities. No paralysis, weakness, dizziness,
changes in vision, or numbness/tingling to bilateral lower extremities was endorsed; although the
patient did admit to pain in the low back radiating to right thigh.
Physical Exam and Treatment
The physical exam was conducted on musculoskeletal ability, as the correct diagnosis
was missed. The shirt of the patient was not lifted, therefore his skin was not examined. In
general, the patient was not in distress and responded to commands. His upper extremities which
were exposed were appropriate in color, turgor, and did not present with lesions or rash. His
head, ears, eyes, and throat showed: no matted lashes, masses, clear conjunctiva, normocephalic
head, moist pink lips and mucosa, symmetrical eyes and ears. His neck was symmetrical without
masses, and trachea midline. Respirations anterior and posterior were clear and unlabored.
Cardiac rhythm auscultated for murmur, rub, gallops- all which were not present. S1 and S2
present. The abdomen was soft and nontender with audible bowel tones in all four quadrants.
Neurologically, the patient was alert and oriented to self, place, situation, and time. There were
no fleeting of ideas and he was able to hold a conversation with clear speech.
The focused back exam revealed tenderness with vertebral palpation. The patient was
able to follow commands for forward flexion, hyperextension, bilateral lateral flexion with pain
on the right side, and bilateral rotation with grimacing when rotating to the right side.
Extremities revealed no trauma or cyanosis. Gait seemed to have been effected by right sided
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pain with slight limping, but patient was able to get up and down exam table. Leg raise test not
done due to patient stating too much pain when laying on his back. Radial pulses 2+.
Skin exam revealed a classic vesicular rash on the right low back consistent with shingles.
Recommended treatment for this would include: antiviral, tramadol, appropriate use of ongoing
Tylenol at home to not exceed daily limit of 4,000mg. Antivirals discussed were acyclovir or
valacyclovir, which would depend on patients most recent labs, specifically his kidney function;
but currently without a history of any baseline labs and no formal diagnosis of kidney disease or
injury. The patient would be appropriate for either antiviral. Acyclovir at 800mg five times a day
for 7 days, by mouth; or valacyclovir at 1000 mg every 8 hrs for 7 days, by mouth (Albrecht,
Hirsch, & Mitty, 2017). Preference for valacyclovir would be given as frequency of dose is less
and possibly for missed dose decreased (Albrecht, et al., 2017). Follow up for healing
progression or pain continuation would be encouraged.
Education and Discussion
Education regarding transmission of disease would include: avoid contact with
individuals who have not had chickenpox or without the varicella vaccine, especially pregnant
women, premature babies, or any immunocompromised persons (CDC, 2016). The patient would
also need to cover his rash and wash his hands frequently, and refrain from itching or scratching
his rash as the fluid from the lesions can directly spread the virus (CDC, 2016). In addition to
prescribed and OTC medications, the patient could try oatmeal baths, calamine lotion, or a wet
compress to help soothe the skin (CDC, 2016). Of course, the shingles vaccine would need to be
advised for future prevention unless the patient has had a severe reaction to neomycin or gelatin;
patients who are immunocompromised, pregnant women, or anyone with a current acute illness
with fever at 101.3 degrees Fahrenheit or higher (CDC, 2016). If the patient does not remember
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receiving the vaccine or records cannot be found the patient is safe to get another dose, and even
if the patient had shingles in the past they are appropriate for vaccination.
Because we did not have information on whether our patient was vaccinated in the past, nor did
the patient recognize the signs and symptoms of the rash. This patient, in particular, would
benefit from education in regards to possible recurrence, as the virus never leaves the body. If he
does feel that he has exposed at-risk individuals prior to visiting the primary care office, he can
also urge these individuals to notify their primary care provider.

Literature Review
The exam of the 67-year-old Caucasian male, who presented with a chief complaint of
back pain led to a visualization of a vesicular rash. The rash was located on his right lower back
characterized as “pins and needles.” The process in which a diagnosis is made may be skewed by
what we learn to be characteristic signs of one disease. The importance of processing differential
diagnosis is to get down to an accurate conclusion. Ruling out possible outcomes assists in the
critical thinking process. Naturally, after a diagnosis is made, the treatment and plan follow, but
if the disease is one that may reoccur, healthcare practitioners should educate and understand
preventative measures. The recurrence of varicella zoster virus (VZV) is a controversial topic
within current literature. From this review, we uncover that misdiagnoses in the past have created
a controversial topic over speculated rate of recurrence in VZV. We will explore the most
common misdiagnosis discussed within literature, and best practice methods into how to
differentiate a correct diagnosis. Further studies relating to recurrence bring up the importance of
protecting individuals from recurrence. One way of doing this may be to further study the role
vaccines play in HZ and what age is most appropriate for boosters. Finally, the current treatment
method for HZ and the future science has in regards to new antiviral therapy will be discussed.
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Often times during an assessment, healthcare practitioners may recognize characteristic
rashes or symptoms that point towards a specific diagnosis. In our case, the visualized lesions
follow the characteristic VZV presentation, following a dermatome within the basal layer of the
skin (Kinchington, Guedon, & Hendricks, 2012). It is important to note there are also cases that
do not present with any rash (Kinchington, et. al., 2012; Fox, Galetta, Mahalingam, Wellish,
Forghani, & Gilden, 2001). Most of the controversy with recurrence is the differentiation
between herpes simplex virus (HSV) and VZV. All three (HSV-1, HSV-2, VZV) viruses are
acquired with a primary self-resolving infection of the skin or mucosa, which leads to latency
and possible recurrence (Kinchington, et al., 2012). Not only are the viruses similar in
presentation and latency but they share genes that encode similar functions on their host.
Differentiating between HSV and VZV should be understood, as there is controversy of
misdiagnoses of recurrent VZV. As advanced testing emerges, such as polymerase esterase chain
reaction (PCR), practitioners can now better determine HSV versus VZV outbreaks. Studies in
the past (not using PCR but viral culturing) found 25% of outbreaks diagnosed as VZV were, in
fact, HSV (Burkhart, 2002). Approximately one-fourth of herpetic eruptions diagnosed as VZV
are confirmed to truly be HSV cases (Pierson, 2017). As a rule in dermatology, repetitive
herpetic outbreaks are HSV infections until proven to be VZV (Burkhart, 2002). Within the
immunocompetent patient population, there have been confirmed misdiagnosed recurrent VZV
cases, which also create controversy of the real rate of recurrence (Chien, Andy, & Olerud,
2007). Sticking to the most up to date facts on differentiating one virus from the other will be
critical in correct diagnosis, treatment, and prevention for our patients. Current laboratory
diagnostics that can assist in differentiation include PCR, enzyme-linked immunosorbent assays,
and immunofluorescence (Burkhart, 2002).
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VZV is known to target the bodies immune system and establish a latency similar to
HSV. The virus is transmitted through aerosol and inhalation. One difference is that VZV
becomes dormant in multiple sensory neuronal nuclei, which gives the virus the ability to
reoccur anywhere in the body (Kinchington, et al., 2012). While HSV lesions tend to affect one
or few neurons and recur at the primary site of infection (Kinchington, et al., 2012). The area of
the primary infection does not always foreshadow the recurrent location in HZ. Another variance
between HSV and VZV is that recurrence rates increase with age whereas with HSV the
recurrence rate drops with age (Kinchington, et al., 2012). Currently, the rate of recurrence of
VZV and the mechanism behind how the virus maintains a latent state is unknown (Kinchington,
et al.,2012). Due to the fact that VZV is much more reliant on host; current animal model
mimicking viral recurrence is rare or nonexistent. Kinchington, et al. (2012) also state the
extreme difficulty of reactivating human ganglia to study the recurrence of VZV.
Since we do know the recurrence rate correlates to immune system functioning,
specifically the degradation of it, our older population will be at increased risk. HSV recurrence
is triggered by both environmental and physiologic factors, VZV is not as closely linked to such
triggers (Kinchington, et al., 2012). Our older individuals are at a higher risk for recurrence due
to immune senescence. Although rash does not always present, 90% of patients with VZV suffer
from pain which almost always involves neurological roots (Kinchington, et al., 2012).
Pain is another characteristic that differentiates VZV from HSV. Because pain can be a
debilitating complication from VZV, the issue of recurrence should be worrisome for current
healthcare professionals. The pain occurs during the active disease and the possibility of chronic
postherpetic neuralgia (PHN) is also well known. PHN is pain that persists for 3 or more months
after the VZV lesions crust (Tseng, Lewin, Hales, Sy, Harpaz, Bialek, et al., 2015). Kinchington,
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et al. (2012) state that HZ patients develop PHN at a rate of more than 30%. The Centers for
Disease Control (2016) states approximately 13% or more of individuals over the age of 60 to be
at risk for PHN. This pain can lead to depression, insomnia, and decreased activity to name a
few. In regards to developing PHN Tseng, et al. (2015) found that vaccination prior to VZV
decreased rates of PHN in women.
Nakamura, et al (2016) found that Japanese patients age 50-79 years old had less severe
pain associated with recurrent VZV versus primary VZV infection. Individuals 80 years old or
older did not experience this less severe recurrence. This might be the case as cell-mediated
immunity in the recurrent individuals were stronger in the 50-79-year-old population (Nakamura,
et al., 2016). Not only is recurrent pain noted to be less severe, but also the lesion development
was less severe in crusting, erythema, vesicles, pustules, erosions, ulcerations, and fusion of
vesicles (Nakamura, et al., 2016). Depending on the age when the patient develops their primary
VZV infection, the immune response will be varied. This means if a patient experiences primary
VZV infection later in life the weaker the immune booster response will be. The implication of
this information is that the older population is predisposed to a recurrence that is closer to their
primary date of infection, along with similar pain and lesion to their primary experience. In this
particular study, no difference was noted between genders or immunocompetent versus
immunocompromised patients (Nakamura, et al., 2016).
Studies have proved the efficacy of the HZ vaccine to be 51.3% effective in preventing
HZ in adults at 60 years old or older, but the protection wearing off with time (Levin, Schmader,
Lei, Williams-Diaz, Zerbe, et al., 2016). Levin, et al. (2016) has confirmed that giving the zoster
vaccine at an earlier age (particularly at age 60 years old), prior to 70 years old or older produces
an increase in the cell immunity response. Although the vaccine's cell-mediated immunity
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persists for 10 years or more, a booster has shown to enhance the immunity for older populations
(Levin, et al., 2016). The question now is when to give the booster, as the age and primary
infection date vary, this all plays a role in the longevity of the immune system's reaction to the
vaccine. Levin, et al (2016) suggests further studies in order to investigate appropriate booster
interval for immunization against HZ.
Currently, the Advisory Committee on Immunization Practices (ACIP) states that the
zoster vaccine is most appropriate at the starting age of 60 years old. The United States Food and
Drug Administration (FDA) has approved the vaccine for individuals 50 years old and older
(CDC, 2016). There is no recommendation for a booster, but rather focusing on the appropriate
age to administer the initial vaccine. The CDC (2016) states the efficacy of the zoster vaccine to
be uncertain after the first 5 years. Current vaccination recommendations state to administer the
shingles vaccine at age 60 years old, as this time is prime for highest risk of zoster and its
complications.
Tseng, et al (2012) have confirmed this in their study showing a slightly higher trend to
decrease VZV recurrence in individuals less than 70 years old when vaccinated; but they also
mention the low recurrence rate overall in immunocompetent individuals and also raise the issue
of possible vaccine shortage. Jumaan, et al. (2005) state that the rise in varicella vaccine for
children has not been the reason for increased zoster virus incidence in adults. Therefore, the
trend for increased incidence in VZV is still unknown, though currently we know it has been
increasing prior to varicella vaccine in the United States (CDC, 2016).
In regards to current treatment, Albrecht et al. (2017) suggest antiviral therapy if onset
has been 72 hours or less, in order to gain the maximum benefit. Patients that are
immunocompromised should receive treatment no matter if the initial 72-hour onset has passed,
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and for all individuals actively experiencing new lesions (even past 72-hour onset) are
appropriate candidates for antiviral therapy (Albrecht, et al., 2017). The drug of choice depends
on patients and their renal function, as acyclovir clears via the kidneys. The top choices for
antiviral therapy are valacyclovir or famciclovir, as the doses are less frequent and the efficacy
has been studied to be the same (Albrecht, et al. 2017). Additional therapies for symptoms
related to pain include narcotics, NSAIDS, and/or Acetaminophen – depending on the pain
rating. Bowsher (1997) studied the efficacy of using tricyclic antidepressants, particularly
amitriptyline for treatment of neuritis or to prevent PHN, but without significant results as there
were many limitations. Other more effective methods of treating acute herpes zoster pain are
oxycodone, although constipation is a well-known side effect; but gabapentin proved not to be
any greater than placebo (Dworkin et al., 2009). Lastly, some providers may choose to use
corticosteroids to improve acute symptoms, but with patients who present with uncomplicated
herpes zoster, the course does not seem to prevent PHN (Han, Zhang, Chen, Zhou, & Zhu,
2013).
Although some practitioners may believe that recurrence of VZV is rare, there is current
evidence to show otherwise. This itself should warrant healthcare practitioners to include
recurrent VZV as a differential when assessing patients with classic signs and symptoms. Yawn,
Wollan, Kurland, St Sauver, & Saddier (2011) have found that recurrence is as common as
primary VZV infection; but rare within the first 12-18 months after the primary HZ episode
(Tseng, 2012). Hales, et al. (2016) revealed recurrent VZV patients were not as likely to seek
healthcare unless pain was severe; suggesting that prior studies using healthcare data may have
underestimated the recurrent rate of VZV. Women are also more likely to suffer from VZV
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recurrence (Hales, Harpaz, & Bialek, 2016.) Currently, the treatment for recurrent VZV is the
same as the primary infection (Albrecht, et al., 2017).
More studies are being conducted on the best antiviral treatment for herpes zoster. As
viruses mutate and become resistant, newer drugs have been made. For example, valacyclovir
which is approved for VZV treatment may be a better choice than the traditional acyclovir, a
guanosine analog. This is the case because valacyclovir has an increased absorption and
bioavailability (De, Hart, & Breuer, 2015). A newer drug has gone through phase 2 trial, called
valacyclovir has been found to be noninferior to valacyclovir in treating herpes zoster (De, et. al.,
2015). For patients who have passed the 72-hour mark and now have encrusted lesions the
benefits of antiviral are minimal (Albercht, et al., 2017). The individuals who benefit most from
antiviral therapy are patients older than 50 years old who have a history of pain lasting longer
with their zoster; but overall the antiviral’s are given to reduce severity of pain and increase the
healing time of skin (Albrecht, et al., 2017). If secondary bacterial infections or complications in
the eye occur then additional treatment therapy is to be added and antiviral therapy may be
prolonged (Albercht, et al., 2017).
Returning to our initial 67-year-old male patient, his case is uncomplicated VZV,
presenting classically with dermatomal vesicular rash and acute neuritis, PCR is unlikely needed
to confirm diagnosis, although further investigation into past history could be useful for
documentation to determine likelihood of HSV or if this current case is recurrent. Since he also
presented before the 72-hour window, the patient was a good candidate for an antiviral,
preferably valacyclovir. For prevention of recurrence, we would want to educate on receiving
vaccination and keeping up with health maintenance as he ages. Managing ongoing comorbidities will be key to keeping his immune system as healthy as possible. Healthcare
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providers can additionally take time to educate patients if acute neuritis is felt (as it can precede
the rash) they may make an appointment to be assessed for antiviral therapy early on, as to
prevent PHN.

Learning Points
•

The current and past rate of recurrent VZV is not known. There have been documented
findings that have re-evaluated the research on VZV. These findings have concluded that
previous studies have misdiagnosed VZV recurrence when the real infection was HSV.

•

The most recent research shows that most individuals with recurrence do not seek
healthcare, unless their pain is severe.

•

So why should we care about herpes zoster recurrence? The answer is clear; as the older
population continues to age and live longer the recurrence rate can also rise. Since we
know that VZV rates increase with age and decline in immunity, our efforts to further
prevent discomfort are valid, as pain can be debilitating.

•

Further studies are needed in order to determine if boosters may assist in prevention, and
in what age group that would be most effective.

•

Overall, keeping recurrent VZV as a differential diagnosis in the back of our minds for
patients most at risk: women, older age, immunocompromised patients; does not hurt our
practice. If laboratory testing is needed, PCR is the most sensitive to distinguish between
HSV.

•

Vaccinating individuals at or after the age of 60 years old is best practice and gives the
best preventative coverage.
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